Dr Justine Reise is the Director of Operations for the UKCRC registered Imperial Clinical Trials Unit (ICTU) in the School of Public Health within the Faculty of Medicine at Imperial College.
A graduate in Biochemistry from University College London, with a PhD in Pharmacology / Analytical Chemistry from Imperial College London, Justine has over 25 years experience of conducting clinical research within academia and aligned with the National Health Service.
At ICTU, she provides senior business and research management expertise to drive the strategic development of the Unit and ensure ongoing successful delivery of Unit objectives. Justine leads a multi-disciplinary team of research and research related - staff working across a portfolio of interventional and observational studies. The portfolio encompasses all clinical phases of drug & device development, across multiple therapeutic areas including surgery, oncology, emergency medicine, mental health and obesity with specific interests in translational research, stratified medicine and Patient and Public Involvement and Engagement. She is responsible for ensuring all Unit activities are undertaken to the highest scientific and regulatory standards whilst maximising the quality, efficiency and effectiveness within financial boundaries.
et al., 2013, The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study, Plos One, Vol:8, ISSN:1932-6203
et al., 2013, An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study), Annals of Oncology, Vol:24, ISSN:0923-7534, Pages:924-930
et al., 2012, Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study, Journal of Clinical Oncology, Vol:30, ISSN:0732-183X, Pages:709-717
et al., 2011, An Open-Label Positron Emission Tomography Study To Investigate and Quantify Brain and Tumor Penetration of Carbon 11-Labeled Lapatinib in Patients with HER2-Overexpressing Advanced or Metastatic Breast Cancer., Cancer Research, Vol:71, ISSN:0008-5472
et al., 2011, Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients With Node-Positive Breast Cancer, Journal of Clinical Oncology, Vol:29, ISSN:0732-183X, Pages:3247-3254